Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 1/2022

01-01-2022 | Lymphoma | EDITORIAL

The Question That Doesn’t Seem to Go Away: Cancer Risk of Anti-TNF Therapy

Author: Oren Ledder

Published in: Digestive Diseases and Sciences | Issue 1/2022

Login to get access

Excerpt

Anti-tumor necrosis factor (TNF) therapy has revolutionized the treatment of inflammatory bowel disease (IBD) over the past two decades; for much of this period, the unresolved question of the potential cancer risk of this class of drug has been overshadowed by its therapeutic successes. Pediatric-onset IBD per se is associated with an increased risk of cancer overall, primarily of skin, lymphoid, and gastrointestinal origin according to large population studies [1, 2]. In these, the risk estimates were similar regardless of exposure to corticosteroids, thiopurines, and/or anti-TNF therapy. …
Literature
1.
Olen O, Askling J, Sachs MC et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964–2014. BMJ 2017;358:j3951CrossRef
2.
Kjaergaard VS, Jensen CB, Elmahdi R, Burisch J, Allin KH, Jess T. Cancer risk in pediatric-onset inflammatory bowel disease: a population-based Danish cohort study. Gastroenterology 2020;159:1609–1611CrossRef
3.
Kotlyar DS, Lewis JD, Beaugerie L et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2015;13:847–858 (quiz e48-50).CrossRef
4.
Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361–371CrossRef
5.
Nyboe Andersen N, Pasternak B, Basit S et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014;311:2406–2413CrossRef
6.
Osterman MT, Sandborn WJ, Colombel JF et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology 2014;146:941–949CrossRef
7.
Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 2014;12:1443–1451 (quiz e88-9).CrossRef
8.
Chupin A, Perduca V, Meyer A, Bellanger C, Carbonnel F, Dong C. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1289–1297PubMed
9.
Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. J Crohns Colitis 2020.
10.
Metadata
Title
The Question That Doesn’t Seem to Go Away: Cancer Risk of Anti-TNF Therapy
Author
Oren Ledder
Publication date
01-01-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06883-w

Other articles of this Issue 1/2022

Digestive Diseases and Sciences 1/2022 Go to the issue

EDITORIAL

Dialing Back M for Monoclonal: Successful De-escalation of Dose-Intensified Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Original Article

Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study

Editorial

Disparities in Telehealth for Liver Disease: Revealing What Was Hidden in Plain Sight

DDS–SIRC COOPERATIVE CONFERENCES

AL Lambda Amyloidosis Activates Acute Liver Failure in the Absence of Plasma Cell Dyscrasia

Original Article

A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC

Original Article

Protective Effect of Luminal Uric Acid Against Indomethacin-Induced Enteropathy: Role of Antioxidant Effect and Gut Microbiota

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits